Molecular Residual Disease (MRD)

What MRD is? ​

Molecular Residual Disease (MRD) testing is a powerful tool for predicting the likelihood of cancer recurrence or progression, surpassing traditional methods, and informing treatment decisions through the analysis of circulating tumor DNA (ctDNA).
Rapid generation of the patient-specific signature

Actionable insights from a single blood sample (< 8 mL)


Ultra-sensitive and accurate


14 working days

turn-around time


Real time cancer monitoring with a single blood test

After effective medical treatment, such as tumor resection, a small quantity of residual cancer cells may remain in the body, undetectable to the resolution of standard-of-care imaging scans. MRD testing enables the identification of ultra-low levels of cancer cells present in the body.

Uncovering trends by using real-world data

Circulating Tumor DNA Allows for Early Detection of Recurrence And Precise Measurement of Tumor Burden.

Our ultra-sensitive test detects molecular traces of ctDNA through comprehensive tracking of the entire tumor mutation signature including aggregating complex features such as CNV and SNV. Therefore, an ultra-low number of cells can be detected compared to standard-of-care imaging.

A standardized workflow

Our standardized workflow from the test shipment to providing MRD report has been designed to ensure consistency, accuracy, and efficiency at every stage of the process.

Tests shipment

After confirmation of the order, we dispatch the test kits

All included test

After confirmation of the order, we dispatch the test kits, which include a solid biopsy block/slides holder and a barcoded blood collection tube, to the designated medical institution.

Sequencing

Filter out noise and derive patient specific cancer mutational signature

Whole genome sequencing

We identify the genetic pattern of a patient’s tumor using thousands of data points across the entire genome.

Data processing

MRD technology utilizes artificial intelligence that recognizes patient-specific cancer patterns

AI & Advanced Signal Processing

MRD technology utilizes artificial intelligence that recognizes tumor specific genomic patterns to provide unprecedented acuity in cancer detection and monitoring.

Monitoring report

Our team of oncology experts reviews each report
        

Clinical validation by scientific team

Our team of oncology experts reviews each report before making it available for the clinician

A technology that enables a faster time to market for pharma companies

Increase clinical trials efficiency

Enhanced efficiency, reduced overall costs, and achieve a clearer demonstration of the long-term durability of treatment responses.

Accelerate drug development

Enable Pharma partners towards genomics-driven drug development, leading to quicker and more cost-effective drug development.

Frequently Asked Questions

C2inform is a personalized qualitative diagnostic tumor informed test for the circulating tumor DNA (ctDNA) – based Molecular Residual Disease (MRD) assessment by using whole-genome sequencing (WGS) data for patients previously diagnosed with solid cancer.

MRD test is designed to be highly sensitive and specific. It can detect extremely low levels of circulating tumor DNA (ctDNA) in a patient’s blood, allowing for the identification of residual cancer cells that might go undetected by conventional biomarker tests.

MRD test provides results in the form of a binary score (positive or negative).

Test Positive: Estimated detection score is above or equal to a pre-defined threshold value – indicates MRD detection

Test Negative: Estimated detection score is below a pre-defined threshold value – indicates MRD non-detection. A negative test result does not definitely indicate the absence of cancer. 

Data is generated from WGS analysis of the following specimen types from each patient: Tumor tissue sample (Formalin Fixed Paraffin Embedded (FFPE)), whole blood for both germline DNA from Peripheral Blood Mononuclear Cells (PBMCs), and plasma for circulating tumor DNA (ctDNA).